Review



sch529074 compound  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress sch529074 compound
    (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM <t>SCH529074</t> compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .
    Sch529074 Compound, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sch529074+compound/SCH529074/pmc12052144-377-9-11
    Average 93 stars, based on 3 article reviews
    sch529074 compound - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "iSoMAs: Finding isoform expression and somatic mutation associations in human cancers"

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers

    Journal: PLOS Computational Biology

    doi: 10.1371/journal.pcbi.1012847

    (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM SCH529074 compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .
    Figure Legend Snippet: (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM SCH529074 compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .

    Techniques Used: Western Blot, Generated, Expressing, Control, Mutagenesis, Comparison, Quantitative Proteomics, Cell Cycle Assay, Derivative Assay

    Related Articles

    Western Blot:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Generated:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Expressing:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Control:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Mutagenesis:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Comparison:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Quantitative Proteomics:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Cell Cycle Assay:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Derivative Assay:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Nucleic Acid Electrophoresis:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Quantitative RT-PCR:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Standard Deviation:

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers
    Article Snippet: Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.Cells were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight.. Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).. Cells were grown for an additional 24 hours and harvested for protein or RNA.Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.
    Article Snippet: cells PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1012847 March 7, 2025 29 / 39 per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.

    Article Title: SoMAS: Finding somatic mutations associated with alternative splicing in human cancers
    Article Snippet: were initially seeded at 0.5 x 10 5 cells per well in a 6 well plate and grown overnight. .. Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment). .. Cells were grown for an additional 24 hours and harvested for protein or RNA.



    Similar Products

    97
    ATCC sch529074 compound nci h1975 cells
    Sch529074 Compound Nci H1975 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sch529074+compound/NCI-H1975/pm40053523-415-6-13
    Average 97 stars, based on 1 article reviews
    sch529074 compound nci h1975 cells - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    93
    MedChemExpress sch529074 compound
    (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM <t>SCH529074</t> compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .
    Sch529074 Compound, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sch529074+compound/SCH529074/pmc12052144-377-9-11
    Average 93 stars, based on 1 article reviews
    sch529074 compound - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Schering-Plough corporation sch529074 compound 71
    (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM <t>SCH529074</t> compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .
    Sch529074 Compound 71, supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sch529074+compound/sch529074+compound+71/pm22404097-346-0-6
    Average 90 stars, based on 1 article reviews
    sch529074 compound 71 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM SCH529074 compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .

    Journal: PLOS Computational Biology

    Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers

    doi: 10.1371/journal.pcbi.1012847

    Figure Lengend Snippet: (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM SCH529074 compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .

    Article Snippet: Culture medium was replaced with medium containing 6 μM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).

    Techniques: Western Blot, Generated, Expressing, Control, Mutagenesis, Comparison, Quantitative Proteomics, Cell Cycle Assay, Derivative Assay